ATE466030T1 - Neues screening-verfahren - Google Patents
Neues screening-verfahrenInfo
- Publication number
- ATE466030T1 ATE466030T1 AT03705107T AT03705107T ATE466030T1 AT E466030 T1 ATE466030 T1 AT E466030T1 AT 03705107 T AT03705107 T AT 03705107T AT 03705107 T AT03705107 T AT 03705107T AT E466030 T1 ATE466030 T1 AT E466030T1
- Authority
- AT
- Austria
- Prior art keywords
- salt
- screening process
- new screening
- eicosanoid
- amino acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 150000002066 eicosanoids Chemical class 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002037131 | 2002-02-14 | ||
| JP2002204163 | 2002-07-12 | ||
| JP2002328696 | 2002-11-12 | ||
| JP2003014032 | 2003-01-22 | ||
| PCT/JP2003/001483 WO2003068959A1 (fr) | 2002-02-14 | 2003-02-13 | Nouveau procede de criblage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466030T1 true ATE466030T1 (de) | 2010-05-15 |
Family
ID=27739281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03705107T ATE466030T1 (de) | 2002-02-14 | 2003-02-13 | Neues screening-verfahren |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7214495B2 (de) |
| EP (1) | EP1479768B1 (de) |
| AT (1) | ATE466030T1 (de) |
| AU (1) | AU2003211952A1 (de) |
| DE (1) | DE60332320D1 (de) |
| WO (1) | WO2003068959A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
| EP1559422B1 (de) * | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Mittel zur kontrolle der rezeptorfunktion |
| EP1584925B1 (de) * | 2003-01-17 | 2011-06-01 | Takeda Pharmaceutical Company Limited | Neues screening-verfahren |
| CA2534467A1 (en) * | 2003-08-18 | 2005-02-24 | Betagenon Ab | New diabetes type 2 animal model |
| WO2005080412A1 (en) * | 2004-02-23 | 2005-09-01 | Theratechnologies Inc | Modulators of fatty acid-stimulated insulin secretion and uses thereof |
| US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US20080004227A1 (en) * | 2004-03-01 | 2008-01-03 | Pharmafrontier Co., Ltd | Pharmaceutical Composition for Lowering Blood Sugar Level |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| US20060003344A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| US20070122344A1 (en) * | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
| EP1929310A2 (de) * | 2005-09-02 | 2008-06-11 | Arena Pharmaceuticals, Inc. | Menschlicher g-protein-gekoppelter rezeptor und modulatoren davon zur behandlung von atherosklerose und einer atherosklerosekrankheit sowie zur behandlung von leiden in verbindung mit der expression von mcp-1 |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| US8252521B2 (en) | 2005-11-04 | 2012-08-28 | Eisai R&D Management Co., Ltd. | Method of screening substance useful in treating disease with the use of GPR40 and phospholipase |
| EP1980148B1 (de) * | 2006-01-31 | 2013-03-20 | Takeda Pharmaceutical Company Limited | Genetisch modifiziertes tier und seine verwendung |
| CA2646430A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| AU2007293028B2 (en) * | 2006-09-07 | 2012-05-31 | Amgen Inc. | Heterocyclic GPR40 modulators |
| US20080161744A1 (en) | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
| CA2683751C (en) * | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| JP5420400B2 (ja) * | 2007-04-26 | 2014-02-19 | 国立大学法人京都大学 | Ｇタンパク質共役型レセプター作動剤 |
| US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
| US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
| MX2010009654A (es) * | 2008-03-06 | 2010-09-28 | Amgen Inc | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. |
| US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
| EP2687235A3 (de) | 2008-05-02 | 2014-11-05 | Novadaq Technologies Inc. | Verfahren zur Herstellung und Verwendung substanzbeladener Erythrozyten (S-LES) zur Beobachtung und Behandlung von mikrovaskulärer Hämodynamik |
| CA2739888C (en) * | 2008-10-15 | 2013-11-19 | Amgen Inc. | Spirocyclic gpr40 modulators |
| US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
| EP2863801B8 (de) | 2012-06-21 | 2024-06-12 | Stryker Corporation | Quantifizierung und analyse von angiografie und perfusionen |
| US9816930B2 (en) | 2014-09-29 | 2017-11-14 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
| CN107427247B (zh) | 2014-10-09 | 2021-06-04 | 史赛克欧洲运营有限公司 | 使用荧光介导的光电容积描记法的组织中的绝对血液流动的定量 |
| EP3580609B1 (de) | 2017-02-10 | 2023-05-24 | Stryker European Operations Limited | Handhaltbare offenfeld-fluoreszenzbildgebungssysteme und verfahren |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US7241579B2 (en) * | 2000-12-22 | 2007-07-10 | Smithkline Beecham Corporation | Method of screening for GPR40 ligands |
| GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
-
2003
- 2003-02-13 US US10/504,726 patent/US7214495B2/en not_active Expired - Fee Related
- 2003-02-13 AT AT03705107T patent/ATE466030T1/de not_active IP Right Cessation
- 2003-02-13 DE DE60332320T patent/DE60332320D1/de not_active Expired - Lifetime
- 2003-02-13 WO PCT/JP2003/001483 patent/WO2003068959A1/ja not_active Ceased
- 2003-02-13 EP EP03705107A patent/EP1479768B1/de not_active Expired - Lifetime
- 2003-02-13 AU AU2003211952A patent/AU2003211952A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7214495B2 (en) | 2007-05-08 |
| EP1479768A1 (de) | 2004-11-24 |
| DE60332320D1 (de) | 2010-06-10 |
| AU2003211952A1 (en) | 2003-09-04 |
| EP1479768B1 (de) | 2010-04-28 |
| EP1479768A4 (de) | 2006-02-01 |
| WO2003068959A1 (fr) | 2003-08-21 |
| US20050089866A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE466030T1 (de) | Neues screening-verfahren | |
| ATE490323T1 (de) | Adiponektin-rezeptor und dafür kodierendes gen | |
| WO2002084286A1 (en) | Screening method | |
| DE60224536D1 (de) | Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae | |
| ATE536406T1 (de) | Neuartiger zytokin-zcytor17-ligand | |
| IN2014CN02050A (de) | ||
| SE9704836D0 (sv) | Novel receptor | |
| DE602005009856D1 (de) | Verfahren zur reinigung von fsh | |
| ATE511644T1 (de) | Neues screening-verfahren | |
| NO20031033D0 (no) | Reseptor i EDb-fibronectindomene | |
| WO2003021262A1 (fr) | Procede de criblage | |
| ATE494550T1 (de) | Neues screening-verfahren | |
| WO2003082320A1 (fr) | Nouveau procede de criblage | |
| CY1109904T1 (el) | Προαγωγεας της il-18bp, η παρασκευη και χρηση του | |
| ATE445159T1 (de) | Neues screening-verfahren | |
| EP1559721A4 (de) | Neue fprl1-liganden und deren verwendung | |
| WO2005100386A3 (en) | Canine cold-and menthol-sensitive receptor 1 | |
| DE60323052D1 (de) | Zwei gonadotropin-freisetzende hormone und methode zur isolierung | |
| WO2003021263A1 (fr) | Utilisation d'une proteine de recepteur couple a une proteine g | |
| EP1467207A4 (de) | Screening-verfahren | |
| SE9902763D0 (sv) | Novel receptor | |
| WO2002061074A1 (fr) | Nouvelle proteine et adn la comprenant | |
| DE50312447D1 (de) | Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin | |
| WO2002029053A1 (fr) | Nouvelle proteine de recepteur couple a la proteine g et adn correspondant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |